Traditional and emerging antifungal therapies

Proceedings of the American Thoracic Society

Volumn 7, Issue 3, 2010, Pages 222-228

  Arnold, Tamra M ^a   Dotson, Emily ^a   Sarosi, George A ^b   Hage, Chadi A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azoles; Echinocandins; Invasive fungal infection; Polyenes

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TRIAZOLE DERIVATIVE; VORICONAZOLE; LIPOPEPTIDE; PYRIMIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANTIFUNGAL ACTIVITY; CHILL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; ELECTROLYTE DISTURBANCE; FEVER; HEADACHE; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOCOMPROMISED PATIENT; METABOLIC ACIDOSIS; NAUSEA; NEPHROTOXICITY; RESPIRATORY TRACT DISEASE; REVIEW; RIGOR; SYSTEMIC MYCOSIS; VOMITING; CLASSIFICATION; DRUG COMBINATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LIPOPEPTIDES; PYRIMIDINES; TRIAZOLES;

EID: 77955488613     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.200906-048AL     Document Type: Review

References (77)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
2. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
3. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693. (Pubitemid 32221925)
4. Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003;6:67-83. (Pubitemid 37207242)
5. Burgess JL, Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med 1972;53:77-84.
6. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 1998;26:334-338.
7. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989;87:547-552. (Pubitemid 19274759)
8. Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, Branch RA. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40:302-308.
9. Cheng JT, Witty RT, Robinson RR, Yarger WE. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int 1982;22:626-633. (Pubitemid 13204106)
10. Heyman SN, Stillman IE, Brezis M, Epstein FH, Spokes K, Rosen S. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J Am Soc Nephrol 1993;4:69-80.
11. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-582. (Pubitemid 32234532)
12. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001;45:922-926. (Pubitemid 32182046)
13. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-388. (Pubitemid 34816321)
14. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al.; National institute of allergy and infectious diseases mycoses study group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-771. (Pubitemid 29114295)
15. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302. (Pubitemid 28365752)
16. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718. (Pubitemid 27386554)
17. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin b for induction therapy of histoplasmosis in patients with aids. Ann Intern Med 2002;137:105-109. (Pubitemid 34779154)
18. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of america. Clin Infect Dis 2007;45:807-825.
19. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA. Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of america. Clin Infect Dis 2008;46:1801-1812.
20. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE. Practice guidelines for the management of cryptococcal disease: infectious diseases society of america. Clin Infect Dis 2000;30:710-718.
21. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29:198-210. (Pubitemid 351438997)
22. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-180. (Pubitemid 18037468)
23. Pappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, Hamill R, Sharkey PK, Chapman SW, Sobel JD. Alopecia associated with fluconazole therapy. Ann Intern Med 1995;123:354-357.
24. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535.
25. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coccidioidomycosis: Infectious Diseases Society of America. Clin Infect Dis 2000;30:658-661.
26. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-426. (Pubitemid 19140050)
27. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of h2 blockers. J Clin Pharmacol 1997;37:535-540. (Pubitemid 27265655)
28. Kanda Y, Kami M, Matsuyama T, Mitani K, Chiba S, Yazaki Y, Hirai H. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998;16:33-37. (Pubitemid 28509019)
29. Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000;45:371-373. (Pubitemid 30139249)
30. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-344. (Pubitemid 19083614)
31. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707-713.
32. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-1767. (Pubitemid 32524211)
33. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, Hecht FM, Powderly W; AIDS clinical trial group. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-342.
34. Service RF. Pharmacogenomics: going from genome to pill. Science 2005;308:1858-1860.
35. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.
36. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of america. Clin Infect Dis 2008;46:327-360. (Pubitemid 351265310)
37. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008;28:614-645. (Pubitemid 351620030)
38. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211. (Pubitemid 351269158)
39. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
40. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-222. (Pubitemid 38223535)
41. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-220. (Pubitemid 40188942)
42. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-1438.
43. Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, Laughlin M, Swan S. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-192. (Pubitemid 40490442)
44. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004;48:4063-4066. (Pubitemid 39304651)
45. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-3551. (Pubitemid 39129357)
46. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347. (Pubitemid 46148776)
47. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-1734. (Pubitemid 43839438)
48. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-2015.
49. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, et al. Experimental pulmonary aspergillosis due to aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003;188:305-319. (Pubitemid 36898165)
50. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359. (Pubitemid 46148777)
51. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-785. (Pubitemid 41688982)
52. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. (Pubitemid 44968977)
53. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-133. (Pubitemid 43042912)
54. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-e65.
55. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-1403.
56. Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005;40:1770-1776. (Pubitemid 40799946)
57. Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, Patel R, McNicholas PM, Goldman M. Activity of newer triazoles against histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006;57:1235-1239. (Pubitemid 44644433)
58. Proia LA, Trenholme GM. Chronic refractory phaeohyphomycosis: successful treatment with posaconazole. Mycoses 2006;49:519-522. (Pubitemid 44511107)
59. Notheis G, Tarani L, Costantino F, Jansson A, Rosenecker J, Friederici D, Belohradsky BH, Reinhardt D, Seger R, Schweinitz DV, et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006;49:37-41. (Pubitemid 44370101)
60. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-1151. (Pubitemid 37222342)
61. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-222.
62. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-1178.
63. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-1457.
64. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3:71-97.
65. Stone J, Holland S, Li P. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin [abstract]. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) Washington, DC: American Society for Microbiology; 2001.
66. Fromtling RA. Micafungin sodium (fk-463). Drugs Today (Barc) 2002;38:245-257. (Pubitemid 34429288)
67. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment [abstract]. Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases (Glasgow, UK). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2003. P-1222.
68. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-457. (Pubitemid 34087195)
69. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-849. (Pubitemid 39244300)
70. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-775. (Pubitemid 39244288)
71. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029. (Pubitemid 35461658)
72. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-661. (Pubitemid 41667052)
73. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-2482. (Pubitemid 46919773)
74. De Sarro A, La Camera E, Fera MT. New and investigational triazole agents for the treatment of invasive fungal infections. J Chemother 2008;20:661-671.
75. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996;40:2243-2247. (Pubitemid 26328023)
76. Clemons KV, Martinez M, Calderon L, Stevens DA. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob Agents Chemother 2002;46:922-924. (Pubitemid 34157691)
77. Marino M, Mummaneni V, Norton J, Hadjilambris O. Ravuconazole exposure-response relationship in hiv+ patients with oropharyngeal candidiasis. American Society for Microbiology 2001 Chicago, IL 2001:393 2001:(Abstract J-1622).